Researchers track side effects of haemophilia drug without extra patient visits
NCT ID NCT04682145
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gathers safety information from a European registry for people with haemophilia A who are treated with turoctocog alfa pegol. Researchers will count any side effects reported to the registry that might be linked to the drug. About 50 participants are involved, and there are no extra tests or visits required.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novo Nordisk Investigational Site
Søborg, 2860, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an ultra-long-acting factor VIII simplify surgery for hemophilia a patients?
- Patient voices take center stage in haemophilia a treatment decisions
- Japanese study tracks Esperoct's Real-World safety over two years
- Japanese hemophilia patients monitored on alhemo in new safety study
- New hope for haemophilia a patients: immune tolerance induction may eliminate clotting factor blockers
- New hope for kids with hemophilia: can SCT800 stop bleeds before they start?